MCID: ZKF001
MIFTS: 47

Zika Fever

Categories: Blood diseases, Infectious diseases, Neuronal diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Zika Fever

MalaCards integrated aliases for Zika Fever:

Name: Zika Fever 12 52 15
Zika Virus Infection 52 58 3 43 71
Zika Virus Disease 12 52 58
Zika Virus 74 42

Characteristics:

Orphanet epidemiological data:

58
zika virus disease
Inheritance: Not applicable; Prevalence: 1-5/10000 (Brazil); Age of onset: All ages; Age of death: adult;

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:0060478
MeSH 43 D000071243
ICD10 32 A92.8
ICD10 via Orphanet 33 U06
Orphanet 58 ORPHA448237
UMLS 71 C0276289

Summaries for Zika Fever

MedlinePlus : 42 Zika is a virus that is spread mostly by mosquitoes. A pregnant mother can pass it to her baby during pregnancy or around the time of birth. It can spread through sexual contact. There have also been reports that the virus has spread through blood transfusions. There have been outbreaks of Zika virus in the United States, Africa, Southeast Asia, the Pacific Islands, parts of the Caribbean, and Central and South America. Most people who get the virus do not get sick. One in five people do get symptoms, which can include a fever, rash, joint pain, and conjunctivitis (pinkeye). Symptoms are usually mild, and start 2 to 7 days after being bitten by an infected mosquito. A blood test can tell whether you have the infection. There are no vaccines or medicines to treat it. Drinking lots of fluids, resting, and taking acetaminophen might help. Zika can cause microcephaly (a serious birth defect of the brain) and other problems in babies whose mothers were infected while pregnant. The Centers for Disease Control and Prevention recommends that pregnant women do not travel to areas where there is a Zika virus outbreak. If you do decide to travel, first talk to your doctor. You should also be careful to prevent mosquito bites: Use insect repellent Wear clothes that cover your arms, legs, and feet Stay in places that have air conditioning or that use window and door screens Centers for Disease Control and Prevention

MalaCards based summary : Zika Fever, also known as zika virus infection, is related to encephalitis and west nile encephalitis, and has symptoms including fever, rash and headaches. An important gene associated with Zika Fever is CD40LG (CD40 Ligand), and among its related pathways/superpathways is Peginterferon alpha-2a/Peginterferon alpha-2b Pathway (Hepatocyte), Pharmacodynamics. The drugs Hydroxychloroquine and Ivermectin have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye, and related phenotypes are arthritis and microcephaly

Disease Ontology : 12 A viral infectious disease that has material basis in Zika virus, which is transmitted by Aedes aegypti mosquitoes and targets neural progenitor cells and neuronal cells in all stages of maturity and has symptom fever, has symptom rash, has symptom headaches and has symptom joint pain.

NIH Rare Diseases : 52 Zika virus infection is spread to people primarily through the bite of an infected mosquito. Zika virus can also be spread from a pregnant mother to her child and through sexual contact with an affected partner. Cases of Zika virus transmission via blood transfusion have also been reported. Zika virus outbreaks are currently occurring in many countries. The illness associated with Zika virus infection is usually mild, with symptoms lasting for several days to a week. The most common symptoms of Zika are fever, rash, joint pain, and conjunctivitis (red eyes). However, research has suggested an association between Zika virus infection and Guillain-Barre syndrome (GBS) in a small percentage of cases. Zika virus infection during pregnancy can cause adverse pregnancy outcomes, including microcephaly and other serious brain defects. The full range of health problems associated with Zika virus infection during pregnancy is currently being studied. No vaccine currently exists to prevent Zika virus infection, but there are still ways to protect oneself. The CDC recommends that pregnant women consider postponing travel to Zika-affected areas. People living in or traveling to areas where Zika virus is found should take steps to prevent mosquito bites . Those who have traveled to Zika-affected areas may wish to take steps to prevent sexual transmission of the Zika virus.

CDC : 3 Zika is spread mostly by the bite of an infected Aedes species mosquito (Ae. aegypti and Ae. albopictus). These mosquitoes bite during the day and night. Zika can be passed from a pregnant woman to her fetus. Infection during pregnancy can cause certain birth defects. There is no vaccine or medicine for Zika.

Wikipedia : 74 Zika virus (ZIKV) (pronounced /ˈziːkə/ or /ˈzɪkə/) is a member of the virus family Flaviviridae. It is... more...

Related Diseases for Zika Fever

Diseases related to Zika Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 329)
# Related Disease Score Top Affiliating Genes
1 encephalitis 31.3 ERVW-1 CD40LG CD209
2 west nile encephalitis 30.1 PRNT CD40LG
3 measles 29.9 STAT2 IFNAR1 CD40LG CD209
4 asymptomatic dengue 29.8 SENP8 PRNT CD40LG
5 acalculous cholecystitis 29.8 SENP8 CD40LG
6 dengue hemorrhagic fever 29.8 STAT2 IFNAR1 CD40LG CD209
7 west nile fever 29.7 PRNT ERVW-1 CD40LG CD209
8 ebola hemorrhagic fever 29.7 SCARA3 ERVW-1 CD40LG
9 dengue shock syndrome 29.6 SENP8 ERVW-1 CD40LG CD209
10 st. louis encephalitis 29.3 SENP8 PRNT ERVW-1 CD40LG
11 dengue disease 29.3 SENP8 PRNT ERVW-1 CD40LG CD209
12 viral infectious disease 29.3 STAT2 IFNAR1 ERVW-1 CD40LG CD209
13 yellow fever 28.9 SENP8 PRNT IFNAR1 FGA
14 zika virus congenital syndrome 12.8
15 torch syndrome 11.3
16 hydrocephalus, congenital, 1 10.7
17 alkuraya-kucinskas syndrome 10.5
18 congenital amyoplasia 10.5
19 toxoplasmosis 10.5
20 glioblastoma multiforme 10.4
21 hydrocephalus 10.4
22 syphilis 10.4
23 tick-borne encephalitis 10.4
24 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.4
25 lissencephaly 10.4
26 neuroblastoma 10.4
27 stomatitis 10.4
28 cytokine deficiency 10.3
29 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.3
30 phlebotomus fever 10.3 PRNT CD40LG
31 autoimmune disease 10.3
32 neural tube defects 10.3
33 cerebellar hypoplasia 10.3
34 infertility 10.3
35 acute disseminated encephalomyelitis 10.3
36 transverse myelitis 10.3
37 primary microcephaly 10.3
38 sensorineural hearing loss 10.3
39 demyelinating polyneuropathy 10.3
40 placenta disease 10.3
41 chikungunya 10.3
42 polymicrogyria with or without vascular-type ehlers-danlos syndrome 10.2
43 middle east respiratory syndrome 10.2
44 male infertility 10.2
45 cerebral palsy 10.2
46 purpura 10.2
47 polymicrogyria 10.2
48 pachygyria 10.2
49 yemenite deaf-blind hypopigmentation syndrome 10.2
50 visual epilepsy 10.2

Graphical network of the top 20 diseases related to Zika Fever:



Diseases related to Zika Fever

Symptoms & Phenotypes for Zika Fever

Human phenotypes related to Zika Fever:

58 (show all 34)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 arthritis 58 Frequent (79-30%)
2 microcephaly 58 Very rare (<4-1%)
3 vomiting 58 Occasional (29-5%)
4 fever 58 Frequent (79-30%)
5 edema 58 Occasional (29-5%)
6 skin rash 58 Very frequent (99-80%)
7 pruritus 58 Frequent (79-30%)
8 arthralgia 58 Frequent (79-30%)
9 myalgia 58 Frequent (79-30%)
10 intrauterine growth retardation 58 Very rare (<4-1%)
11 thrombocytopenia 58 Very rare (<4-1%)
12 lens subluxation 58 Very rare (<4-1%)
13 iris coloboma 58 Very rare (<4-1%)
14 conjunctivitis 58 Frequent (79-30%)
15 meningitis 58 Very rare (<4-1%)
16 headache 58 Frequent (79-30%)
17 subcutaneous hemorrhage 58 Very rare (<4-1%)
18 encephalitis 58 Very rare (<4-1%)
19 spontaneous abortion 58 Very rare (<4-1%)
20 optic disc hypoplasia 58 Very rare (<4-1%)
21 wrist swelling 58 Occasional (29-5%)
22 abnormality of the optic disc 58 Very rare (<4-1%)
23 increased circulating igm level 58 Frequent (79-30%)
24 macular atrophy 58 Very rare (<4-1%)
25 maculopapular exanthema 58 Very frequent (99-80%)
26 retinal pigment epithelial mottling 58 Very rare (<4-1%)
27 ankle swelling 58 Occasional (29-5%)
28 abnormality of the cerebrospinal fluid 58 Frequent (79-30%)
29 chorioretinal atrophy 58 Very rare (<4-1%)
30 myelitis 58 Very rare (<4-1%)
31 acute demyelinating polyneuropathy 58 Very rare (<4-1%)
32 absent foveal reflex 58 Very rare (<4-1%)
33 transient hearing impairment 58 Occasional (29-5%)
34 congenital intracerebral calcification 58 Very rare (<4-1%)

Symptoms:

12
  • fever
  • rash
  • headaches
  • joint pain

Drugs & Therapeutics for Zika Fever

Drugs for Zika Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 20)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydroxychloroquine Approved Phase 3 118-42-3 3652
2
Ivermectin Approved, Investigational, Vet_approved Phase 3 70288-86-7 6474909
3 Anti-Infective Agents Phase 3
4 Antiparasitic Agents Phase 3
5 Antiprotozoal Agents Phase 3
6 Antirheumatic Agents Phase 3
7 Antimalarials Phase 3
8 Immunologic Factors Phase 2
9
Aluminum sulfate Approved Phase 1 10043-01-3
10
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
11 Immunoglobulins, Intravenous Phase 1
12 Rho(D) Immune Globulin Phase 1
13 gamma-Globulins Phase 1
14 Immunoglobulin G Phase 1
15 Antibodies, Blocking Phase 1
16 Antibodies Phase 1
17 Immunoglobulins Phase 1
18 Antibodies, Monoclonal Phase 1
19 Vaccines Phase 1
20 Pharmaceutical Solutions Phase 1

Interventional clinical trials:

(show top 50) (show all 67)
# Name Status NCT ID Phase Drugs
1 Randomized, Double-Blind, Controlled, Parallel Group Study With the INTERCEPT Blood System for RBCs in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections and Treatment Use Open-Label Extension Study Recruiting NCT03037164 Phase 3
2 Efficacy and Safety of Hydroxychloroquine and Ivermectin in Hospitalized no Critical Patients Secondary to COVID-19 Infection: Randomized Controlled Trial Recruiting NCT04391127 Phase 3 Hydroxychloroquine;Ivermectin;Placebo
3 VRC 705: A Phase 2/2B, Randomized Trial to Evaluate the Safety, Immunogenicity and Efficacy of a Zika Virus DNA Vaccine in Healthy Adults and Adolescents Completed NCT03110770 Phase 2
4 A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA 1325 Zika Vaccine in Healthy Adults in a Non-endemic Zika Region Completed NCT03014089 Phase 1
5 A Phase 1, Randomized, Double-Blind Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of an Accelerated Vaccination Schedule With a Zika Virus Purified Inactivated Vaccine Plus Alum Adjuvant in Healthy Adults Completed NCT02937233 Phase 1
6 VRC 320: A Phase I, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA090-00-VP, Administered Via Needle and Syringe or Needle-free Injector, PharmaJet, in Healthy Adults Completed NCT02996461 Phase 1
7 Safety and Pharmacokinetic Evaluation of Zika Virus Immune Globulin in Healthy Volunteers Completed NCT03624946 Phase 1
8 A Randomized, Placebo-controlled, Observer-blinded Phase 1 Study to Assess the Safety and Immunogenicity of Two Different Dose Levels of an Alum Adjuvanted Inactivated Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Flavivirus-naïve Adults Aged 18 to 49 Years Completed NCT03425149 Phase 1
9 Phase I, Open-label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5700 Administered ID Followed by EP in Dengue Virus-Naïve Adults Completed NCT02809443 Phase 1
10 Double Blinded, Randomized, Placebo Controlled, Dose Finding Trial to Evaluate the Optimal Dose of MV-ZIKA, a New Vaccine Against Zika Virus, in Regard to Immunogenicity, Safety, and Tolerability in Healthy Volunteers Completed NCT02996890 Phase 1
11 Phase I, Placebo-Controlled, Double-Blind Study To Evaluate The Safety, Tolerability, AND Immunogenicity Of GLS-5700, Administered ID Followed By Electroporation In Dengue Virus-Seropositive Adults Completed NCT02887482 Phase 1
12 Phase I Evaluation of the Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults Completed NCT03611946 Phase 1
13 Phase 1 First in Human, Time Lagged, Parallel-Group, Single Ascending Dose Study of Tyzivumab in Healthy Adult Volunteers Completed NCT03443830 Phase 1 Tyzivumab
14 VRC 319: A Phase I/Ib, Randomized Clinical Trial to Evaluate the Safety and Immunogenicity of A Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults Completed NCT02840487 Phase 1
15 Phase 1, Double-blinded, Placebo-Controlled Study of the Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered by the Intramuscular Route in Flavivirus Naïve Adult Subjects Completed NCT02952833 Phase 1 Saline
16 A Phase 1, First-in-Human, Double-blinded, Randomized, Placebo-controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of an Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) in Healthy Flavivirus-Naïve and Flavivirus-Primed Subjects Completed NCT02963909 Phase 1
17 Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v, a Universal Mosquito-Borne Disease Vaccine Completed NCT03055000 Phase 1
18 Phase 1 First-in-Human, Time Lagged, Single Ascending Dose Study of TY014 in Healthy Adult Volunteers (Safety Arm - 1A) and Sequential Time Lagged, Parallel-Group, Randomised, Placebo-Controlled, Double-Blind, Single Ascending Dose Study of TY014 in YF-17D Vaccine Strain-Challenged Healthy Adult Volunteers (Efficacy Arm - 1B) Completed NCT03776786 Phase 1
19 Observer Blinded, Randomized Trial to Evaluate Safety and Immunogenicity of a Novel Vaccine Formulation MV-ZIKA-RSP Recruiting NCT04033068 Phase 1
20 Phase 1 Time Lagged, Parallel-Group, Randomized, Placebo-Controlled, Single-Blind, Single Ascending Dose Study of Tyzivumab in ZIKV Infected Patients Recruiting NCT03776695 Phase 1
21 A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Zika Virus (ZIKV) Vaccine ChAdOx1 Zika in Healthy Adult Volunteers Given as a Standalone Vaccine or Co-administered With the Chikungunya Virus (CHIKV) Candidate Vaccine ChAdOx1 Chik Recruiting NCT04015648 Phase 1
22 A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults Active, not recruiting NCT04064905 Phase 1
23 A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Safety, Immunogenicity, and Dose Ranging Study of Purified Inactivated Zika Virus Vaccine (PIZV) Candidate in Flavivirus Naïve and Primed Healthy Adults Aged 18 to 49 Years Active, not recruiting NCT03343626 Phase 1 Placebo
24 Phase I, Randomized, Double-blinded, Placebo-Controlled Dose De-escalation Study to Evaluate the Safety and Immunogenicity of Alum Adjuvanted Zika Virus Purified Inactivated Vaccine (ZPIV) Administered by the Intramuscular Route in Adult Subjects Who Reside in a Flavivirus Endemic Area Active, not recruiting NCT03008122 Phase 1
25 Estimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection. Unknown status NCT03161444
26 Persistence of Zika Virus in Semen After Acute Infection Unknown status NCT02733796
27 Études Observationnelles Des conséquences néonatales et pédiatriques de l'Infection à Virus Zika au Cours de la Grossesse Pendant l'épidémie Des départements français d'Amérique de l'année 2016 Unknown status NCT02810210
28 Études Observationnelles Des conséquences de l'Infection à Virus Zika au Cours de la Grossesse Pendant l'épidémie Des départements français d'Amérique de l'année 2016 Unknown status NCT02916732
29 Effect of a Posture Adapter Use on Body Alignment in Standing Position on Children Between 12 and 24 Months Old With Zyka Virys Congenital Syndrome Unknown status NCT03227601
30 Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment: Cohort Study in Fiocruz/IFF Unknown status NCT03255369
31 Prospective Surveillance and Case Definition Study of Zika Virus Disease and Infection in Adolescents and Adults in Latin America in Preparation for an Efficacy Trial of a Zika Virus Whole Virion, Purified Inactivated Vaccine Completed NCT03158233
32 The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico (Zik01) Completed NCT02831699
33 Evaluation of the Clinical Performance of the ZIKV Detect™ 2.0 IgM Capture ELISA Completed NCT03776903
34 Sensorimotor Outcomes of Children Exposed to Foetal Zika Virus Infection During the First or Second Trimester of Gestation. Completed NCT03679728
35 Understanding Excretion and Infectivity of Zika Virus in Semen During and After Infection Completed NCT02979938
36 Rash Accompanied by Three or More Dengue-like Symptoms During Pregnancy and Microcephaly: Case-control Study Completed NCT02741882
37 Study of Zika Virus and Related Arbovirus Infections in Deferred Blood Donors Completed NCT02794181
38 Efficacy of Aquatic Physiotherapy in Stress Level and Muscle Tone of Children Between 3 and 24 Months With Microcephaly by Zika Virus Congenital Syndrome Completed NCT03330600
39 Pilot Study to Detect Zika Virus in Sperm Completed NCT02874456
40 Neurovirus Emerging in the Americas Study (NEAS): Neurologic Manifestations of the Arbovirus Dengue, Chikungunya and Zika Infections in Colombia Completed NCT03206541
41 Randomized Trial to Assess Parental Response to Different Presentations of Vaccination Data for Schools and Child Care Centers Completed NCT02957344
42 TRMC-Bio "Molecular Profiling of Gut Microbiome, Microbiome Metabolome, Serum Chemistry, and Metabolism-Associated SNPs in Elite Athletes" Completed NCT02818413
43 Spatial Repellent Products for Control of Vector-borne Diseases - Dengue Completed NCT03553277
44 Pilot Study to Detect DENGUE Virus in Sperm. Completed NCT03612609
45 Risk Evaluation of Fetal Nervous System and Neurodevelopment Disorders in Infants of Women Exposed to Zika Virus Infection During Pregnancy Recruiting NCT02943304
46 Descriptive and Prognostic Study of Arbovirus Infections in France, Based on a Hospital Cohort of Children and Adults With Suspected Arbovirose.r Recruiting NCT01099852
47 Children (CH) Cohort for the Evaluation of Developmental and Neurological Abnormalities in Infants Born to Mothers Residing in Areas With Zika Virus Transmission During Pregnancy Recruiting NCT03393286
48 World Mosquito Program - Colombia (WMP-COLOMBIA): The Impact of City-wide Deployment of Wolbachia-infected Mosquitoes on Arboviral Disease Incidence in Medellin and Bello, Colombia Recruiting NCT03631719
49 The International Cohort Study of Children Born to Women Infected With Zika Virus During Pregnancy Recruiting NCT04118738
50 Neuro-COVID-19: Neurological Complications of COVID-19 Recruiting NCT04418609

Search NIH Clinical Center for Zika Fever

Cochrane evidence based reviews: zika virus infection

Genetic Tests for Zika Fever

Anatomical Context for Zika Fever

MalaCards organs/tissues related to Zika Fever:

40
Brain, Testes, Eye, T Cells, Skin, Placenta, Fetal Brain

Publications for Zika Fever

Articles related to Zika Fever:

(show top 50) (show all 1430)
# Title Authors PMID Year
1
Characterization of Placental Infection by Zika Virus in Humans: A Review of the Literature. 61 42
32559805 2020
2
Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines. 42
32560145 2020
3
RIG-I Plays a Dominant Role in the Induction of Transcriptional Changes in Zika Virus-Infected Cells, which Protect from Virus-Induced Cell Death. 42
32560274 2020
4
Structure-activity relationship of flavonoid bifunctional inhibitors against Zika virus infection. 61
32272109 2020
5
Brain Iron Accumulation and the Formation of Calcifications After Developmental Zika Virus Infection. 61
32483612 2020
6
The involvement of annexin A1 in human placental response to maternal Zika virus infection. 61
32360947 2020
7
The P-MAPA immunomodulator partially prevents apoptosis induced by Zika virus infection in THP-1 cells. 61
32484769 2020
8
7-Deaza-7-Fluoro-2'-C-Methyladenosine Inhibits Zika virus Infection and Viral-induced Neuroinflammation. 61
32574688 2020
9
Forced Zika Virus Infection of Culex pipiens Leads to Limited Virus Accumulation in Mosquito Saliva. 61
32575394 2020
10
Zika virus detection in amniotic fluid and Zika-associated birth defects. 61
31954155 2020
11
A Single-Center Experience with a Pregnant Immigrant Population and Zika Virus Serologic Screening in New York City. 61
31146294 2020
12
Experience in diagnosing congenital Zika syndrome in Brazilian children born to asymptomatic mothers. 61
32165128 2020
13
Insecticide resistance, fitness and susceptibility to Zika infection of an interbred Aedes aegypti population from Rio de Janeiro, Brazil. 61
32513248 2020
14
Zika virus infection in asymptomatic persons in Myanmar, 2018. 61
32043531 2020
15
T cell immunity rather than antibody mediates cross-protection against Zika virus infection conferred by a live attenuated Japanese encephalitis SA14-14-2 vaccine. 61
32556415 2020
16
Vesicular stomatitis virus and DNA vaccines expressing Zika virus nonstructural protein 1 (NS1) induce substantial but not sterilizing protection against Zika virus infection. 61
32554698 2020
17
A direct-acting antiviral drug abrogates viremia in Zika virus-infected rhesus macaques. 61
32522808 2020
18
Performance of an Automated Zika IgG Immunoassay in the Detection of Zika IgG Specific Antibodies-A Validation Approach in Samples from Prevalence Areas and Non-Endemic Countries. 61
32521651 2020
19
A unique immune signature of serum cytokine and chemokine dynamics in patients with Zika virus infection from a tropical region in Southern Mexico. 61
32081772 2020
20
Neurological outcomes of congenital Zika syndrome in toddlers and preschoolers: a case series. 61
32199080 2020
21
Comparative analysis of a Thai congenital-Zika-syndrome-associated virus with a Thai Zika-fever-associated virus. 61
32474686 2020
22
Emergence of Zika virus infection in China. 61
32427996 2020
23
Malaria in the Pregnant Traveler. 61
32419013 2020
24
Long-term alterations in brain and behavior after postnatal Zika virus infection in infant macaques. 61
32439858 2020
25
Discordant Zika Virus Findings in Twin Pregnancies Complicated by Antenatal Zika Virus Exposure: A Prospective Cohort. 61
31773163 2020
26
Role of Prenatal Ultrasonography and Amniocentesis in the Diagnosis of Congenital Zika Syndrome: A Systematic Review. 61
32282593 2020
27
Evolutionary analysis of the Musashi family: What can it tell us about Zika? 61
32422351 2020
28
Maternal Zika Virus (ZIKV) Infection following Vaginal Inoculation with ZIKV-Infected Semen in Timed-Pregnant Olive Baboons. 61
32188737 2020
29
Women's Awareness and Healthcare Provider Discussions about Zika Virus during Pregnancy, United States, 2016-2017. 61
32310074 2020
30
Functional Outcomes among a Cohort of Children in Northeastern Brazil Meeting Criteria for Follow-Up of Congenital Zika Virus Infection. 61
32228785 2020
31
The effects of Japanese encephalitis virus antibodies on Zika virus infection. 61
32078028 2020
32
Basic insights into Zika virus infection of neuroglial and brain endothelial cells. 61
32375993 2020
33
Induced Pluripotent Stem Cell (iPSC)-Based Neurodegenerative Disease Models for Phenotype Recapitulation and Drug Screening. 61
32344649 2020
34
New Challenge for Zika Virus Infection: Human Reservoirs? 61
32311307 2020
35
CD4+ T Cells Cross-Reactive with Dengue and Zika Viruses Protect against Zika Virus Infection. 61
32348763 2020
36
Modulation in phase and frequency of neural oscillations during epileptiform activity induced by neonatal Zika virus infection in mice. 61
32317689 2020
37
IL-27 signaling activates skin cells to induce innate antiviral proteins and protects against Zika virus infection. 61
32270034 2020
38
Guillain-Barré syndrome related to Zika virus infection: A systematic review and meta-analysis of the clinical and electrophysiological phenotype. 61
32339199 2020
39
Absence of Evidence of Zika Virus Infection in Cord Blood and Urine from Newborns with Congenital Abnormalities, Indonesia. 61
32043460 2020
40
Schinus terebenthifolius Raddi extracts: from sunscreen activity toward protection of the placenta to Zika virus infection, new uses for a well-known medicinal plant. 61
32346222 2020
41
Dengue fever complicated by liver dysfunction due to possible co-infection with hepatitis E in a returning traveller from Cuba. 61
32172268 2020
42
Age-dependent manifestations and case definitions of paediatric Zika: a prospective cohort study. 61
31870907 2020
43
ZIKA Virus infection in pregnant women in French Guiana: More precarious-more at risk. 61
32208419 2020
44
Emerging and neglected zoonoses in transplant population. 61
32257849 2020
45
Author Correction: Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection. 61
32001822 2020
46
Zika virus infection studies with CD34+ hematopoietic and megakaryocyte-erythroid progenitors, red blood cells and platelets. 61
32086956 2020
47
Zika virus infection in chemosensory cells. 61
32144727 2020
48
IRE1α Promotes Zika Virus Infection via XBP1. 61
32138181 2020
49
Vaccination with Aedes aegypti AgBR1 Delays Lethal Mosquito-Borne Zika Virus Infection in Mice. 61
32218189 2020
50
Different populations of Aedes aegypti and Aedes albopictus (Diptera: Culicidae) from Central Africa are susceptible to Zika virus infection. 61
32203510 2020

Variations for Zika Fever

Expression for Zika Fever

Search GEO for disease gene expression data for Zika Fever.

Pathways for Zika Fever

Pathways related to Zika Fever according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
9.98 STAT2 IFNAR1

GO Terms for Zika Fever

Cellular components related to Zika Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.02 TYRO3 FGA CD40LG CD209 AXL

Biological processes related to Zika Fever according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 viral entry into host cell GO:0046718 9.58 TYRO3 CD209 AXL
2 JAK-STAT cascade GO:0007259 9.51 STAT2 IFNAR1
3 leukocyte cell-cell adhesion GO:0007159 9.49 CD40LG CD209
4 apoptotic cell clearance GO:0043277 9.48 TYRO3 AXL
5 natural killer cell differentiation GO:0001779 9.46 TYRO3 AXL
6 cellular response to interferon-alpha GO:0035457 9.43 IFNAR1 AXL
7 vagina development GO:0060068 9.37 TYRO3 AXL
8 secretion by cell GO:0032940 9.32 TYRO3 AXL
9 ovulation cycle GO:0042698 9.26 TYRO3 AXL
10 negative regulation of lymphocyte activation GO:0051250 9.16 TYRO3 AXL
11 forebrain cell migration GO:0021885 8.96 TYRO3 AXL
12 platelet activation GO:0030168 8.92 TYRO3 FGA CD40LG AXL

Molecular functions related to Zika Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol 3-kinase binding GO:0043548 8.96 TYRO3 AXL
2 virus receptor activity GO:0001618 8.8 TYRO3 CD209 AXL

Sources for Zika Fever

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....